Overall, the prospects are great for 2018, says Øystein Soug in a press release from Targovax.
Two of our portfolio companies receive funding in though competition.
Our portfolio company Oncoinvent opened brand-new lab and production facilities at Nydalen Oslo. Now they control the whole production line of their lead product candidate Radspherin. 2017 has been a good year for Oncoinvent. The company has relocated and built new office and laboratory facilities, grown from four to twelve employees, and raised new […]
Our portfolio company PCI Biotech (OSE: PCIB) got an early Christmas present this year. For some time, they have been in dialogue with the regulatory authorities in the US and Europe. On December 20th, they sent out the notice that they in 2018 will start a pivotal, randomized study on the development of fimaporfin in […]
Our portfolio company Nordic Nanovector ASA presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting. The updated data continue to highlight Betalutin®’s strong clinical profile as a single agent for treatment of R/R iNHL, and […]
Nordic Nanovector is ready to initiate the pivotal Phase 2b study, PARADIGME, with Betalutin® in patients with relapsed, anti-CD 20 Ab-refractory FL (R/R FL), a high unmet medical need group, pending approval of the proposed trial design from regulatory authorities. Go to full presentation here PARADIGME is designed to generate the clinical data needed to […]
I følge Dagens Medisin får tre prosjekter innen legemiddelproduksjon og produksjon av medisinsk utstyr 41 millioner kroner av Forskningsrådet. To av prosjektene involverer porteføljebedriftene Oncoinvent og Nordic Nnaovector. Dette er prosjekter som ifølge Forskningsrådet bygger videre på godt etablerte fagmiljøer og aktører, og som skal bidra til å trekke norsk helsenæring i ønsket retning, […]
Our portfolio company Photocure ASA is on the roll in the U.S and reported a revenue growth of 45% for this important market in the third quarter of 2017. Following the new Medicare reimbursement from 2018, Photocure increases the annual revenue ambition for 2020 to a range of USD 20 to 25 million. “Our third […]
Our portfolio company Photocure with more positive news from the the U.S. market. The United States Centers for Medicare & Medicaid Services (CMS) will from January 1, 2018 reimburse hospital outpatient departments for certain Blue Light Cystoscopy (BLC™) with Cysview®. “The effectiveness and benefits of using Blue Light Cystoscopy (BLC) with Cysview for improved detection […]